218
Participants
Start Date
July 1, 2021
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2022
Natesto
Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
RECRUITING
NYU Langone Health, New York
RECRUITING
ProHEALTH Care Associates, Garden City
RECRUITING
AccuMed Research Associates, Garden City
RECRUITING
The Research Foundation for the State University of New York at Buffalo, Williamsville
RECRUITING
Coastal Carolina Research Center, North Charleston
RECRUITING
Urology Center of Florida, Pompano Beach
RECRUITING
NanoHealth Associates, Miami Beach
RECRUITING
University of Miami, Miami
RECRUITING
New Horizon Research Center, Miami
RECRUITING
Precision Clinical Research, Sunrise
RECRUITING
Excel Medical Clinical Trials, Boca Raton
RECRUITING
Florida Healthcare Associates, Boynton Beach
RECRUITING
Alabama Clinical Therapeutics, Birmingham
RECRUITING
Investigative Clinical Research of Indiana, Elwood
RECRUITING
Urology of Indiana, Indianapolis
RECRUITING
Tandem Clinical Research GI, LLC, Marrero
RECRUITING
Preferred Research Partners, Little Rock
WITHDRAWN
Lynn Health Science Institute, Oklahoma City
RECRUITING
Prime Revival Research Institute, Flower Mound
RECRUITING
Baylor College of Medicine, Houston
WITHDRAWN
Coastal Bend Clinical Research, Corpus Christi
RECRUITING
Crossroads Clinical Research, Victoria
WITHDRAWN
North Austin Urology, Austin
WITHDRAWN
Lynn Institute of the Rockies, Colorado Springs
WITHDRAWN
Horizon Clinical Research Associates, Phoenix
WITHDRAWN
Eclipse Clinical Research, Tucson
RECRUITING
Advanced Biomedical Research of America, Las Vegas
RECRUITING
Valley Clinical Trials, Northridge
RECRUITING
Premier Urology Group, Edison
WITHDRAWN
Warren Alpert School of Medicine Brown University, Providence
Lead Sponsor
Acerus Pharmaceuticals Corporation
INDUSTRY